Maze Therapeutics’ (MAZE) “Buy” Rating Reaffirmed at HC Wainwright

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They currently have a $110.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 304.63% from the company’s current price.

Other analysts have also recently issued research reports about the stock. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Wedbush reissued an “outperform” rating and issued a $48.00 target price on shares of Maze Therapeutics in a research note on Wednesday. Citigroup assumed coverage on shares of Maze Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $50.00 target price on the stock. Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, BTIG Research reissued a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research note on Tuesday. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $63.40.

Maze Therapeutics Stock Performance

Shares of MAZE traded down $0.91 during trading hours on Thursday, reaching $27.19. 209,019 shares of the company traded hands, compared to its average volume of 659,310. The stock’s fifty day moving average is $27.18 and its 200 day moving average is $29.17. The stock has a market cap of $1.51 billion, a P/E ratio of -10.79 and a beta of 2.17. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. Maze Therapeutics has a 1-year low of $21.95 and a 1-year high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting analysts’ consensus estimates of ($0.76). Equities research analysts anticipate that Maze Therapeutics will post -2.72 earnings per share for the current fiscal year.

Insider Activity

In other Maze Therapeutics news, insider Courtney Phillips sold 2,012 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $52,332.12. Following the sale, the insider directly owned 7,007 shares of the company’s stock, valued at approximately $182,252.07. This represents a 22.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jason Coloma sold 11,411 shares of the company’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total transaction of $296,800.11. Following the sale, the chief executive officer directly owned 27,362 shares in the company, valued at $711,685.62. This represents a 29.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 191,459 shares of company stock valued at $5,263,539 over the last three months. 5.30% of the stock is owned by corporate insiders.

Institutional Trading of Maze Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. grew its stake in Maze Therapeutics by 10.2% during the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after buying an additional 465,641 shares during the last quarter. TRV GP IV LLC bought a new stake in Maze Therapeutics during the second quarter worth about $133,502,907. ARCH Venture Management LLC bought a new stake in shares of Maze Therapeutics during the second quarter valued at approximately $122,983,582. BlackRock Inc. bought a new stake in shares of Maze Therapeutics during the second quarter valued at approximately $104,525,000. Finally, Jupiter Topco LLC bought a new stake in shares of Maze Therapeutics during the second quarter valued at approximately $101,764,000.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.